FULCRUM THERAPEUTICS, INC. Preferred Stock Dividends, Income Statement Impact
FULCRUM THERAPEUTICS, INC. (FULC) reported Preferred Stock Dividends, Income Statement Impact of $7.13 million for the 12-month period ending 2019-12-31, per its 10-K/A filed 2023-06-23.
Discontinued › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2023-06-23
- FULCRUM THERAPEUTICS, INC. preferred stock dividends, income statement impact for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. preferred stock dividends, income statement impact for the quarter ending 2019-09-30 was $796.00K, a 57.16% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. preferred stock dividends, income statement impact for the quarter ending 2019-06-30 was $3.29M, a 213.43% increase year-over-year.
- FULCRUM THERAPEUTICS, INC. preferred stock dividends, income statement impact for the quarter ending 2019-03-31 was $3.04M.
- FULCRUM THERAPEUTICS, INC. preferred stock dividends, income statement impact for fiscal 2019 was $7.13M, a 8.68% increase from fiscal 2018.
- FULCRUM THERAPEUTICS, INC. preferred stock dividends, income statement impact for fiscal 2018 was $6.56M.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-23 | $796.00K derived: sum of 2 quarters · filed 2023-06-23 | $4.09M derived: sum of 3 quarters · filed 2023-06-23 | $7.13M 10-K/A · filed 2023-06-23 |
| 2019-09-30 | $796.00K 10-Q · filed 2020-11-10 | $4.09M derived: sum of 2 quarters · filed 2020-11-10 | $7.13M 10-Q · filed 2020-11-10 | $9.95M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | $3.29M 10-Q · filed 2020-08-11 | $6.33M 10-Q · filed 2020-08-11 | $9.15M derived: sum of 3 quarters · filed 2020-08-11 | $11.01M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | $3.04M 10-Q · filed 2020-05-13 | $5.86M derived: sum of 2 quarters · filed 2020-05-13 | $7.72M derived: sum of 3 quarters · filed 2020-05-13 | $8.77M derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | $2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $4.68M derived: sum of 2 quarters · filed 2020-03-05 | $5.73M derived: sum of 3 quarters · filed 2020-03-05 | $6.56M 10-K · filed 2020-03-05 |
| 2018-09-30 | $1.86M 10-Q · filed 2019-11-14 | $2.91M derived: sum of 2 quarters · filed 2019-11-14 | $3.74M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $1.05M 10-Q · filed 2019-08-26 | $1.88M 10-Q · filed 2019-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |